DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/jzhg24/b_cell_receptor) has announced the addition of the "B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2015" report to their offering.
Activation of the B cell receptor involves phosphorylation of the cytoplasmic immunoreceptor tyrosine-based activation motifs (ITAMs) present in Ig alpha and beta. This leads to activation of several non-receptor tyrosine kinases including those of the Src, Tec and Syk family of kinases. Downstream messengers include DAG, IP3, MAPK/ERK and JNK signaling modules.
There are today 226 companies plus partners developing 295 B cell receptor pathway targeting drugs in 1308 developmental projects in cancer. In addition, there are 4 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 149 drugs.
B Cell Receptor Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 186 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 181 out of the 184 studied drug targets so far have been recorded with somatic mutations.
The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 42 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Pipeline Breakdown According to Number of Drugs
- Marketed - 29
- Registered - 1
- Pre-registration - 4
- Phase III - 31
- Phase II - 121
- Phase I - 145
- Preclinical - 160
- No Data - 10
- Suspended - 4
- Ceased - 149
Delivery Format: Desktop App plus Online Access to Updates (One Year)
For more information visit http://www.researchandmarkets.com/research/jzhg24/b_cell_receptor
